Intrinsic Value of S&P & Nasdaq Contact Us

CSL Limited CSLLY OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
77/100
6/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$307.00
+1139.4%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

CSL Limited (CSLLY) trades at a trailing P/E of 63.5, forward P/E of 14.2. Trailing earnings yield is 1.57%, forward earnings yield 7.02%. PEG 0.04 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (62/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.04); analyst target implies upside (+1139.4%).
  • Forward P/E 14.2 (down from trailing 63.5) — analysts expect earnings to grow, which would improve the valuation.
  • PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 1.57% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 7.02% as earnings recover.
  • Analyst consensus target $307.00 (+1139.4% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 77/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
77/100
SG Score
View full scorecard →
VALUE
62/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
MOAT
75/100
→ Income
GROWTH
63/100
→ Income
INCOME
70/100
→ Income

Valuation Snapshot — CSLLY

Valuation Multiples
P/E (TTM)63.5
Forward P/E14.2
PEG Ratio0.04
Forward PEG0.04
P/B Ratio0.00
P/S Ratio6.25
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.39
Forward EPS (Est.)$1.74
Book Value / Share$0.00
Revenue / Share$3.96
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.57%
Forward Earnings Yield7.02%
Dividend Yield0.00%
Analyst Target$307.00 (+1139.4%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $1.34 $5.91B $1.27B 21.6%
2017 $1.47 $7.02B $1.02B 14.6%
2018 $1.40 $7.59B $1.27B 16.8%
2019 $2.07 $8.32B $1.92B 23.1%
2020 $2.31 $9.41B $2.17B 23.1%
2021 $2.62 $10.33B $2.39B 23.1%
2022 $1.20 $10.49B $3.11B 29.6%
2023 $2.27 $13.17B $2.19B 16.7%
2024 $2.72 $14.69B $2.64B 18%
2025 $0.39 $15.43B $3B 19.5%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message